Stupp Trial: Improved survival with TMZ Chemotherapy 100 90 80 RT + TMZ 70 RT 60 Probability of OS (%) 50 40 30 20 10 6 12 18 24 30 36 42 Months No. at Risk RT 286 240 144 59 23 2 0 RT+TMZ 257 216 174 109 57 27 4 HR 0.63 (95% Cl, 0.52 to 0.75; p<0.001) Adapted from Scrive et al. ASTRO 2007

Long-term Survival Radiation therapy Combination P value 2 years 10.9% 27.2% P<0.0001 3 years 4.4% 16.0% 4 years 3.0% 12.1% Adapted from Mirimanoff et al. ASTRO 2007.

MGMT Gene Status: Survival at Four Years Radiation therapy Combination therapy P value Methylated MGMT promoter 5.2% 22.1% P<0.04 Non-methylated MGMT promoter 0% 11.1% P=0.035 Adapted from Mirimanoff et al. ASTRO 2007.